Market Intelligence, Clinical Progress, and High-Purity Reagents for NASH, HBV, and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CIDEB drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CIDEB Mutant Recombinant Protein: Full-length WT & CIDE domain truncation. High purity (>95%), Endotoxin <1 EU/ug. Sequence Verified. Theoretical MW confirmed. | View CIDEB Products |
| Gene Delivery | CIDEB Lentivirus Premade Particles: Full-length ORF for stable hepatocyte lipid-droplet assays. HEK293 expressed. CMV or EF1a promoter options. | View CIDEB Products |
| Detection Ab | Anti-CIDEB Recombinant Antibody: High-affinity rabbit mAb for Western/IP/IF/IHC. Sequence Verified. | View CIDEB Products |
| Validator | CIDEB siRNA Set (3 unique sequences): For knockdown verification in lipid-droplet and HBV replication assays. Sequence verified. | View CIDEB Products |
| Related Target A | CIDEA (Brown Adipose Tissue): Paralog with distinct tissue distribution; useful for subfamily selectivity profiling. | View CIDEA Products |
| Related Target B | CIDEC / FSP27 (White Adipose): Complementary lipid-droplet regulator; potential compensatory mechanism in NASH. | View CIDEC Products |
| Related Target C | PNPLA3 (I148M Mutant Available): NAFLD risk allele synergy; lipid droplet co-localization studies. | View PNPLA3 Products |
| Related Target D | HSD17B13: Genetically validated target conferring protection against liver disease. | View HSD17B13 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular lipid-droplet binding & domain mapping | Full-length & N-terminal / CIDE-domain truncation proteins available; HEK293 expressed; >95% purity |
| Cross-species translation & CIDE family selectivity | Human / Mouse / Cyno ortholog proteins strictly Sequence Verified; homolog panel (CIDEB, CIDEA, CIDEC) verified by mass spec |
| Knockdown efficacy validation & specificity controls | Validated siRNA set (3 sequences) and lentivirus ORF for rescue/knockdown specificity controls |
| Lack of reliable detection standards & false positives | Recombinant Anti-CIDEB antibody clone; strictly verified expression protocols (HEK293) with Theoretical MW confirmed |
Live CIDEB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
CIDEB represents an emerging, high-conviction intracellular target at the intersection of metabolic disease and infectious disease. Preclinical data strongly implicate CIDEB in non-alcoholic steatohepatitis (NASH) progression through regulation of lipid droplet fusion and VLDL maturation, as well as in hepatitis B virus (HBV) and hepatitis D virus (HDV) replication as a critical host dependency factor. Large-scale human genetic studies have revealed that loss-of-function variants in CIDEB are highly protective against liver disease, establishing strong genetic validation. The current pipeline resides predominantly in lead optimization and discovery, with the next wave shifting toward orally bioavailable small-molecule disruptors, liver-targeted siRNA/ASO strategies, and PROTAC degraders. As first-generation inhibitors advance through IND-enabling studies, demand for rigorous biochemical and cell-based assays is accelerating. Combination therapies with FXR agonists, THR-β agonists, and other metabolic modulators are expected to become mainstream.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| siRNA / RNAi | Regeneron, Alnylam, Silence Therapeutics | NASH / MASH | In vitro knockdown validation (need lentivirus for target-expressing cell lines and validated siRNA controls) |
| ASO (Antisense) | Ionis, Emerging Biotech | Metabolic Disorders | Selectivity assay (need sequence-verified human/mouse orthologs) |
| Small Molecule (PPI Inhibitor) | Novartis, Takeda, early biotech | NASH, HBV/HDV, Metabolic Syndrome | Homodimerization and lipid droplet displacement assays (need pure full-length and domain-truncation proteins) |
| PROTAC / Degrader | Emerging platform developers | Refractory HBV, severe NASH | Ternary complex & target engagement assays (need purified WT and mutant CIDEB) |
| Gene Editing (CRISPR) | Editas, Intellia, early biotech | Advanced Liver Fibrosis, Rare Metabolic Disorders | Phenotypic screening and isogenic lines (need benchmark antibodies) |
Related Targets for Cross-Selling
Based on lipid droplet biology and NASH/HBV pathways, the following synergistic targets are recommended:
- CIDEA (View CIDEA Products): Brown adipose paralog; useful for tissue-specific selectivity profiling and comparative thermogenesis studies.
- CIDEC / FSP27 (View CIDEC Products): White adipose paralog; key for understanding compensatory lipid droplet fusion mechanisms in NASH.
- PNPLA3 (View PNPLA3 Products): Major NAFLD genetic risk factor (I148M); physically interacts with CIDEB on lipid droplets; mutant protein available.
- HSD17B13 (View HSD17B13 Products): Genetically validated protective target in liver disease; often co-targeted with CIDEB in RNAi pipelines.
Target validation and reagent details are based on UniProt Q9UHD4 and current literature.